Bone Biologics (NASDAQ:BBLG) Releases Quarterly Earnings Results

Bone Biologics (NASDAQ:BBLG) posted its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, FiscalAI reports.

Bone Biologics Stock Performance

BBLG stock traded down $0.02 on Monday, reaching $0.38. The company’s stock had a trading volume of 25,825 shares, compared to its average volume of 145,450. The business has a fifty day simple moving average of $0.52 and a two-hundred day simple moving average of $0.98. Bone Biologics has a 12-month low of $0.37 and a 12-month high of $2.39. The firm has a market cap of $1.04 million, a PE ratio of -0.28 and a beta of 0.90.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a report on Thursday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone.

The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research.